The global Huntington’s disease treatment market size was estimated to be USD 0.472 billion in 2023 and is expected to reach at USD 5.08 billion by 2034 with a CAGR of 24.13% during the forecast period 2024-2034. Rising prevalence of Huntington’s Disease (HD), robust product pipeline for disease-modifying treatments, increasing launch of novel products, surge in product approvals by regulatory bodies, growing research & development activities, surge in number of clinical trials, increasing focus on development of innovative medications for Huntington's disease by major market players are some of the key factors boosting the market growth.
Increasing focus on development of innovative medications for Huntington's disease by major market players is predicted to boost the market growth during the forecast period. Numerous research institutions and governmental entities are offering research funding and technological assistance to expedite the progress of candidate pipelines. For instance, in May 2023, The phase 3 clinical trial of Neurocrine Biosciences' medication valbenazine has demonstrated substantial advancements in the successful management of chorea linked to Huntington's disease.
By drug, tetrabenazine was the highest revenue-grossing segment in the global Huntington’s disease treatment market in 2023 owing to increasing adoption rate due to availability of its generic version and increasing research & development activities for the formulation of innovative treatment for Huntington’s disease. Additionally, deutetrabenzine is predicted to grow at fastest CAGR during the forecast period owing to the negative side effects associated with the medication and rising approvals of novel medications by regulatory bodies. For instance, in February 2023, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. based in the U.S., declared that the U.S. Food and Drug Administration (FDA) has granted approval for AUSTEDOXR (deutetrabenazine) extended-release tablets. This novel once-daily version is intended for use in adults to treat tardive dyskinesia (TD) as well as the chorea linked to Huntington's disease (HD).
By treatment, symptomatic treatment was the highest revenue-grossing segment in the global Huntington’s disease treatment market in 2023 owing to the accessibility of symptom treatment products and their patent protection, increasing research & development activities, rising approvals by regulatory bodies, surge in number of clinical trial procedures. For instance, in June 2023, uniQure N.V. has reported encouraging interim results, which include a follow-up period of up to 24 months, from the ongoing Phase I/II clinical study of AMT-130 for Huntington's disease treatment, involving 26 enrolled patients in the United States. Additionally, disease-modifying therapies is predicted to grow at fastest CAGR during the forecast period owing to rising research & development activities for disease-modifying therapy, increasing demand for gene therapy & stem cell therapy, surge in initiatives by governmental organizations, such as the U.S. FDA's Fast Track Designation for speeding the registration process.
By end-user, hospital pharmacy was the highest revenue-grossing segment in the global Huntington’s disease treatment market in 2023 owing to increasing healthcare infrastructure, access to a large patient population, ties with pharmaceutical stakeholders, & multidisciplinary approach to therapy, and rising approvals of novel drugs by regulatory bodies. For instance, in August 2023, The Food and Drug Administration (FDA) has given its approval for Ingrezza® (valbenazine) to be used in the treatment of chorea linked to Huntington's disease in adults. Additionally, e-commerce is predicted to grow at fastest CAGR during the forecast period owing to the growing usage of smartphone & internet, the simplicity of buying prescription drugs online and the expansion of e-commerce services internationally.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of the disease, increasing technological advancements, rising healthcare expenditure, surge in government initiatives, growing awareness regarding treatment products for Huntington’s disease among patients, and increasing partnership & collaborations within market players. For instance, in May 2023, The Huntington's Disease Society of America (HDSA) and RARE-X, a patient-driven data collection platform under Global Genes, have partnered to create a robust natural history study aimed at expediting knowledge acquisition. This initiative, known as the Huntington's Disease Data Collection Initiative (HD-DCI), empowers individuals with Huntington's disease (HD) to enhance the sharing of their data, thereby expediting the advancement of HD treatments. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the higher product adoption, rising prevalence of Huntington’s disease, increasing number of efforts by governments being undertaken to enhance people’s, and growing collaborations within market players. For instance, in March 2023, UCB, an international biopharmaceutical firm, and Aitia, a pioneer in using Causal AI and 'Digital Twins' for drug discovery, have revealed an early-stage partnership in drug discovery. This collaboration is primarily centered on identifying and confirming new drug targets and potential drug candidates for Huntington's disease. The objective is to validate fresh drug targets that are directly associated with clinical outcomes in Huntington's disease.
Increasing focus on development of innovative medications for Huntington's disease by major market players is predicted to boost the market growth during the forecast period. Numerous research institutions and governmental entities are offering research funding and technological assistance to expedite the progress of candidate pipelines. For instance, in May 2023, The phase 3 clinical trial of Neurocrine Biosciences' medication valbenazine has demonstrated substantial advancements in the successful management of chorea linked to Huntington's disease.
By drug, tetrabenazine was the highest revenue-grossing segment in the global Huntington’s disease treatment market in 2023 owing to increasing adoption rate due to availability of its generic version and increasing research & development activities for the formulation of innovative treatment for Huntington’s disease. Additionally, deutetrabenzine is predicted to grow at fastest CAGR during the forecast period owing to the negative side effects associated with the medication and rising approvals of novel medications by regulatory bodies. For instance, in February 2023, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. based in the U.S., declared that the U.S. Food and Drug Administration (FDA) has granted approval for AUSTEDOXR (deutetrabenazine) extended-release tablets. This novel once-daily version is intended for use in adults to treat tardive dyskinesia (TD) as well as the chorea linked to Huntington's disease (HD).
By treatment, symptomatic treatment was the highest revenue-grossing segment in the global Huntington’s disease treatment market in 2023 owing to the accessibility of symptom treatment products and their patent protection, increasing research & development activities, rising approvals by regulatory bodies, surge in number of clinical trial procedures. For instance, in June 2023, uniQure N.V. has reported encouraging interim results, which include a follow-up period of up to 24 months, from the ongoing Phase I/II clinical study of AMT-130 for Huntington's disease treatment, involving 26 enrolled patients in the United States. Additionally, disease-modifying therapies is predicted to grow at fastest CAGR during the forecast period owing to rising research & development activities for disease-modifying therapy, increasing demand for gene therapy & stem cell therapy, surge in initiatives by governmental organizations, such as the U.S. FDA's Fast Track Designation for speeding the registration process.
By end-user, hospital pharmacy was the highest revenue-grossing segment in the global Huntington’s disease treatment market in 2023 owing to increasing healthcare infrastructure, access to a large patient population, ties with pharmaceutical stakeholders, & multidisciplinary approach to therapy, and rising approvals of novel drugs by regulatory bodies. For instance, in August 2023, The Food and Drug Administration (FDA) has given its approval for Ingrezza® (valbenazine) to be used in the treatment of chorea linked to Huntington's disease in adults. Additionally, e-commerce is predicted to grow at fastest CAGR during the forecast period owing to the growing usage of smartphone & internet, the simplicity of buying prescription drugs online and the expansion of e-commerce services internationally.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of the disease, increasing technological advancements, rising healthcare expenditure, surge in government initiatives, growing awareness regarding treatment products for Huntington’s disease among patients, and increasing partnership & collaborations within market players. For instance, in May 2023, The Huntington's Disease Society of America (HDSA) and RARE-X, a patient-driven data collection platform under Global Genes, have partnered to create a robust natural history study aimed at expediting knowledge acquisition. This initiative, known as the Huntington's Disease Data Collection Initiative (HD-DCI), empowers individuals with Huntington's disease (HD) to enhance the sharing of their data, thereby expediting the advancement of HD treatments. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the higher product adoption, rising prevalence of Huntington’s disease, increasing number of efforts by governments being undertaken to enhance people’s, and growing collaborations within market players. For instance, in March 2023, UCB, an international biopharmaceutical firm, and Aitia, a pioneer in using Causal AI and 'Digital Twins' for drug discovery, have revealed an early-stage partnership in drug discovery. This collaboration is primarily centered on identifying and confirming new drug targets and potential drug candidates for Huntington's disease. The objective is to validate fresh drug targets that are directly associated with clinical outcomes in Huntington's disease.
Segmentation: Huntington’s Disease Treatment Market Report 2022 - 2033
Huntington’s Disease Treatment Market Analysis & Forecast by Drug 2023 - 2034 (Revenue USD Bn)
- Deutetrabenzine
- Tetrabenazine
- Others
Huntington’s Disease Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Disease-modifying Therapies
- Symptomatic Treatment
Huntington’s Disease Treatment Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- E-commerce
- Hospital Pharmacy
- Retail Pharmacy
Huntington’s Disease Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Huntington’s Disease Treatment Market: Drug Estimates & Trend Analysis
8. Huntington’s Disease Treatment Market: Treatment Estimates & Trend Analysis
9. Huntington’s Disease Treatment Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Huntington’s Disease Treatment Market
12. Europe Global Huntington’s Disease Treatment Market
13. Asia Pacific Global Huntington’s Disease Treatment Market
14. Latin America Global Huntington’s Disease Treatment Market
15. MEA Global Huntington’s Disease Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novartis AG
- Lupin
- AOP Health
- H. Lundbeck A/S
- Vaccinex Inc
- Teva Pharmaceutical Industries Ltd.
- Prilenia Therapeutics
- Bausch Health Companies Inc.
- Medesis Pharma SA
- Hetero
- Neurocrine Biosciences
- Hikma Pharmaceuticals PLC
- som biotech
- Dr. Reddy’s Laboratories Ltd.
- UniQure
- Sun Pharmaceutical Industries Ltd.
- Mitochon Pharmaceuticals
- Annexon Biosciences
- PTC Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.47 Billion |
| Forecasted Market Value ( USD | $ 5.08 Billion |
| Compound Annual Growth Rate | 24.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
